Market News

CDMO appoints Anders Högdin and Aaron Small to lead the growth of its pharmaceutical development services business in the US and Europe.

New shareholder, Axxamof Milan, Italy, will transfer certain therapeutic assets to the R&D programs of Acousia.

Additional storage expansion strengthens the facilities’ ability to meet increased customer demand in prefilled syringes.

Company will also close its Hopewell, New Jersey site and will not renew its lease at the Lake Union Steam Plant site in Seattle, Washington.

New once-a-day formulation indicated to improve blood sugar when used along with diet and exercise.

Actions will help to improve the company's financial profile.

Company expects the generic capsules will save up to $500 million during this upcoming season.

Users of LyoSpeed on Series 3 HT Evaporators report a greater percentage of samples yield dry powders than they have previously been able to achieve.

Acquisition would "fit perfectly with Lonza's Healthcare Continuum strategy".

Pharma manufacturers are feeling encouraged to explore new possibilities.

Lucentis the only treatment available for a wide range of CNV conditions.

"MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer's disease."

New company will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis.

Clinically proven and cost-effective solution for gastroesophageal reflux disease recently launched in China.

MJR technology offers reformulation options that can lead to a superior profile for an API.

Pharma giant says it complied with established competition law.

Helps shape better supply chain to pharmaceutical and healthcare Industries.

Move will allow the company to focus efforts and resources more fully on its core US Branded assets.

Investment enables the CDMO to provide a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing.

Combining nivolumab and ipilimumab could provide significant tumour reduction.

The deal allows Lonza to fully focus on developing its other technologies.

SP Scientific's whitepaper emphasis the importance of using external washers to remove particles from the outside of vials.

Brings specialist knowledge of modified release technologies, polymer engineering and science, solids, liquids, semi-solids, nasal delivery, and the switch from prescription to OTC medications

The CDMO’s initiatives include laboratory research for the preparation of APIs, with a particular focus on chiral molecules and emphasis on the principles of sustainable development and ‘green chemistry’.

UCL pioneers the engineering of novel nanoscale drug delivery vehicles, which can be tuned to release a range of cargos.

The new product, Laccure Pessary, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products.

The Dolphin brand is currently the third largest on the Russian market for nasal rinsing.

As regulatory pressure increases companies are saving time and money with effective extractables and leachables programmes.

The added space will house state-of-the-art clean rooms and integrated best-in-class vision equipment.

T2DM therapies are capable of modifying the activity of insulin in the brain.

New entrants, as well as smaller companies, will expand the use of cell culture-based manufacturing methods to increase their presence.

Company to invest more than 100 million euro in dengue vaccine manufacturing plant in Germany

Partnership combines MolPort’s 6.3 Million HTS Compounds with StarDrop’s data analysis and compound design capabilities.

Enables detailed control in thawing of cell and gene therapies.

The silicone capmats reseal after each piercing and may be re-pierced many times without loss of function.

Mechanical thrombectomy is a more effective treatment than clot-busting drugs alone for acute stroke caused by blockage of a large blood vessel by a clot.

Company gains additional API capacity and major supply agreement with Roche

Company acquires two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging.

Enables standardization and audit of remote freezing and thawing.

The license allows Mylan to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of hepatitis C virus.

The increase in diagnosed prevalent cases and the launches of interleukin (IL)-17 inhibitors, such as Eli Lilly’s Taltz and AstraZeneca’s Lumicef, will drive the market.

Domestic sales identified as chief driver behind unexpected rise in revenues.

It's anticipated that 65% of the total NSCLC market will go to immuno-oncology therapies.

Opdivo is now the first and only PD-1 inhibitor approved for a hematologic malignancy in the European Union.

Chase acquisition adds a new Phase III ready program for Alzheimer's disease to Allergan portfolio.

Pomalidomide available to people in England immediately via the Cancer Drugs Fund.

Many companies embracing alternative funding sources, such as angel investors, as investments from VC firms continue to decrease.

Studies suggest calcilytics may represent effective future asthma therapeutics.

The asthma and COPD treatment will be delivered using Vectura’s proprietary dry powder inhalation technology and device.

The company will create a cross-disciplinary Kendall Square campus, with teams spanning research, clinical development, medical affairs, business development and other related functions.

The type 2 diabetes treatment for adults will be delivered using SoloStar technology.

The XEN Glaucoma Treatment System reduces intraocular pressure in patients with refractory glaucoma.

Indication now includes use in children 6 months and older.

Grant will be used to tackle one of the biggest bioproduction problems currently facing the industry

Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options.

The OPTICORE coating technology allows targeted drug release in the large intestine to improve local and/or systemic drug bioavailability.

For patients this could mean more are able to achieve a normal life expectancy, without compromising on their quality of life.

Will coordinate and organize the company’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs.

Therapeutic vaccines will increase the overall survival of poor-performance-status patients, and enable more rounds of treatments to be given, thus driving market growth.

Coating acts as an effective barrier to many of the extractables and leachables that can be released from the elastomer.

Treatment provides the opportunity for fewer infusion sites and shorter infusion durations.

Novo Nordisk’s N9-GP and CSL-Behring’s CSL-689 are expected to be launched in the forecast period and capture significant market share.

The acquisition reflects growing demand for the specialist packaging solutions for powders, minitabs or granules into stickpack sachets.

The spin-off of Bioverativ is on track to be completed in early 2017.

Titan Enterprises offers online informative and unbiased guidance document.

Two-thirds of pharmaceutical manufacturing is outsourced; preferred providers pick up largest share.

There are 90 pipeline cannabinoid products, including two in Phase III development.

The company’s insurance carrier will make a cash payment of $2.0 million to NRM.

Company prepares to start the production of sterile anti-infective injectable products at this site during 2018.

Avecia's Milford site is expected to be the largest cGMP oligonucleotide facility in the world.

Treatment combines two widely used and complementary medicines into a single daily injection for people with type 2 diabetes who are struggling to keep their blood sugar levels under control.

Treatment proven in a Phase III trial to significantly extend overall survival for patients with recurrent or metastatic squamous cell head and neck cancer.

New services to enable US biopharmaceutical companies to accelerate development of biosimilars.

Taytulla 1 mg/20 mcg will provide women with a new and effective option.

CDMO to invest in its facility in Hlohovec, Slovakia, to increase the scale at which it can perform wurster coating of the pellets.

Currently, there is no available drug that can treat the negative symptoms of schizophrenia, according to GlobalData.

Biologics and monoclonal antibodies to become a bigger presence within the small-molecule-dominated landscape.

GlobalData anticipates ALKS-5461 will enter the US market in early 2018.

Potential to be first submission of a proposed biosimilar trastuzumab in the US.

These shark antibodies are considered to have immediate and highly disease-specific potential for the diagnosis and treatment of Alzheimer’s disease.

Merger with sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company.

Allows adult patients with advanced melanoma to receive first-line treatment with the potentially life-extending combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) on the NHS in Scotland.

Merck is the first multinational enterprise to dedicate a large-scale green-field investment (€170 million) to the production of pharmaceuticals on China’s Essential Drug List.

Patent will cover a method of treating a subject having a viral infection caused by an influenza virus with neuraminidase inhibitors in combination with MEK inhibitors.

First early access scheme for breakthrough immunotherapy in blood cancer.

Provides access for patients and streamlined reimbursement.

Four dosage strengths of quetiapine fumarate extended release tablets being distributed.

TraceLink to present on global serialisation strategies at Pharmaceutical Serialisation & Traceability 2016.

As well as increasing output, the company is also investing in new technologies, including flow chemistry, chromatography and hydrogenation capabilities.

10 events to drive India’s rapid pharma growth predicted to reach $55bn by 2020.

Europe to be a key market for the company's phage-based therapies to treat bacterial infections in patients with unmet medical needs.

Amendments to the national immunization schedules of the US and the UK, the expansion of egg-based quadrivalent seasonal influenza vaccines across Germany, Italy, France, and Spain, and the transition from egg-based to cell culture-based vaccines will ...

MorphaBond is an abuse-deterrent formulation of extended release morphine using physical and chemical barriers, without the use of aversive agents or opioid antagonists.

Acquisition adds global rights to highly differentiated compounds to treat multi-factorial elements of NASH.

Gleevec recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx as Best Biotechnology Product.

Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery.

A new delivery system for the nonly FDA-approved treatment to help patients produce more of their own tears.

Acquisition would expand Astellas' oncology pipeline with antibody in late-stage.

Products include an innovative Tool Management System and a new patented elliptical punch head form designed to increase dwell time on an existing table press without the need for time-consuming and expensive modifications.

The injection of capital follows an impressive year of growth for the company.

Award recognizes BMS for driving innovation in immuno-oncology.

Acquisition expands Allergan's gastroenterology pipeline.

The seminars discuss tablet design, tool material selection, tool features and configuration, tooling maintenance and lifecycle management.

Gamlen Tableting to demonstrate its new manufacturability protocol at AAPS.

First dedicated small-molecule manufacturing line to be constructed in Visp, Switzerland.

Pharmapack Awards 2017 closing: Calling all pharma packaging and drug delivery innovators.

New solutions for the packaging process.

Programs include a systematic approach to drug repurposing and data-driven, proactive chronic disease management - both fueled by the IBM Watson Health Cloud.

Provides pan-European availability of widely used and much needed oral liquid version clobazam tablets.

Investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery.

Approval is for first-line treatment of patients whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations.

Executives emphasised the importance of being first to market, two distinct outsourcing strategies, with biopharm and HPAPIs segments reporting strong growth.

The US will not only remain the largest major market for MDD drugs, but will extend its lead over other countries, says GlobalData.

Inflectra will be the first biosimilar monoclonal antibody (mAb) to be available in the US.

Keynote speaker says traditional monolayer cell culture models used to study tumour chemoresistance have proven to be woefully inadequate.

Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from COPD, asthma and other respiratory diseases.

Collaboration will focus on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets.

Will lead the company’s ongoing efforts to anticipate and act upon industry trends and technologies that may affect study sponsors, clinical sites, and patients, and to inform the development and delivery of current and future clinical supply services.

Sterinova to specialise in developing and manufacturing sterile ready-to-use injectable products.

The new facilities includes dedicated cell development suites and new robotic platforms for process automation.